KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Net Income: 2014-2025

Historic Net Income for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Sep 2025 value amounting to $31.6 million.

  • Aurinia Pharmaceuticals' Net Income rose 120.53% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.9 million, marking a year-over-year increase of 443.39%. This contributed to the annual value of $5.7 million for FY2024, which is 107.36% up from last year.
  • Aurinia Pharmaceuticals' Net Income amounted to $31.6 million in Q3 2025, which was up 46.66% from $21.5 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Net Income ranged from a high of $31.6 million in Q3 2025 and a low of -$50.4 million during Q1 2021.
  • Over the past 3 years, Aurinia Pharmaceuticals' median Net Income value was $678,000 (recorded in 2024), while the average stood at $368,545.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' Net Income crashed by 312.71% in 2021 and then skyrocketed by 3,073.01% in 2025.
  • Aurinia Pharmaceuticals' Net Income (Quarterly) stood at -$33.3 million in 2021, then increased by 21.84% to -$26.0 million in 2022, then dropped by 3.34% to -$26.9 million in 2023, then soared by 105.47% to $1.5 million in 2024, then surged by 120.53% to $31.6 million in 2025.
  • Its last three reported values are $31.6 million in Q3 2025, $21.5 million for Q2 2025, and $23.3 million during Q1 2025.